-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the U.
S.
Food and Drug Administration (FDA) approved the Apreude (cabotegravir sustained-release injection suspension ) developed by ViiV Healthcare, a GlaxoSmithKline holding company , for pre-exposure prevention in high-risk adults and adolescents weighing at least 35 kg.
To reduce the risk of sexual infection with HIV .
The administration of Apreude is started with two injections a month apart , and then once every two months .
S.
Food and Drug Administration (FDA) approved the Apreude (cabotegravir sustained-release injection suspension ) developed by ViiV Healthcare, a GlaxoSmithKline holding company , for pre-exposure prevention in high-risk adults and adolescents weighing at least 35 kg.
According to the 2021 Global AIDS Prevention and Control Progress Report, there will be 1.
5 million new HIV infections globally in 2020, a 31% decrease compared with 2010
Pre-exposure prophylaxis (PrEP) is a preventive treatment for HIV, which can be understood as “pre-treatment”, mainly for HIV-negative individuals who are at high risk of HIV infection.
End
Reference materials:
Reference materials:[1] https:// nouncements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention
[1] https:// nouncements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention https:// -events/press-an nouncements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention leave a message here